A Study of SC-005 in Subjects With Triple Negative Breast Cancer (TNBC)

Summary

This is a multicenter, open-label study in participants with triple negative breast cancer (TNBC) to study the safety, tolerability, pharmacokinetics and preliminary efficacy of SC-005. This study consists of 2 parts: Part A (dose regimen finding) followed by Part B (dose expansion).

Timeline

Start

2018-01-04

Primary completion

2018-10-05

Completion

2018-10-05

Outcome

Outcome not reported

Stopped (Business): “Strategic considerations”

Drugs

Indications